Pharming Group N.V.

NasdaqGM PHAR

Pharming Group N.V. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -1.57%

Pharming Group N.V. Return on Capital Employed (ROCE) is -1.57% for the year ending December 31, 2023, a -128.28% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Pharming Group N.V. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was 5.56%, a -27.79% change year over year.
Pharming Group N.V. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 7.70%, a -74.28% change year over year.
Pharming Group N.V. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was 29.92%, a -45.81% change year over year.
Pharming Group N.V. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 55.21%, a 91.69% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

NasdaqGM: PHAR

Pharming Group N.V.

CEO	Dr. Sijmen de Vries M.B.A., M.D.
IPO Date	Dec. 23, 2020
Location	Netherlands
Headquarters	Darwinweg 24
Employees	382
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Key trends

Past 5 years